Melissa Hoganis the Founder and Immediate Past President of Project Alive, a Hunter syndrome research and advocacy foundation. After her youngest son was diagnosed with the rare disease Hunter syndrome (Mucopolysaccharidosis II) in 2009, she left her career as a corporate lawyer and strategy consultant to focus on advancing awareness, education, and research in the Hunter syndrome community. Under her leadership, Project Alive initiated and funded a gene therapy research program that received IND approval and progressed toward enrollment. Now as a principal consultant with Doulots, Ms. Hogan is considered a leading expert on clinical trials for neurodegenerative diseases and has consulted on the design of clinical trials for Hunter syndrome around the world. She is also a principal investigator on patient outcomes initiatives at Project Alive, an FDA Patient Representative, an advisory board member for the Mayo Clinic Social Media Network, and a member of the Foundation Alliance and Corporate Alliance committees of Global Genes.